EKA

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Eureka Energy Limited

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

empty share chartempty share line

Performance graph isn't available yet for this share

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in EKA

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in EKA

N/A
EKA investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in EKA also invest in...

Want more shares? Try these...

Elevate Uranium Ltd

EL8

Elevate Uranium Ltd. is engaged in the exploration and development of uranium properties in Australia and Namibia. The company is headquartered in Perth, Western Australia. The firm is engaged in the exploration and evaluation of its mineral tenements in Namibia and Australia and enhancing the value through the potential application of the Company’s patented U-pgrade uranium beneficiation process to those mineral tenements. Its Namibia tenements include Koppies, Hirabeb, Namib IV, Marenica Uranium Project, and Capri. The firm holds around ten active tenements in the Erongo Region of Namibia, each at varying stages of exploration advancement. The Koppies tenement (EPL 6987) is located in the Namib Desert region of Namibia. The Capri tenement (EPL 7508) is located in the Erongo uranium province in Namibia. In Australia, the Company's tenements consist of the 100% owned Angela, Thatcher Soak, Oobagooma and Minerva Projects and holdings in the Bigrlyi, Malawiri, Walbiri and Areva Joint Ventures. The Angela tenement (EL25758) is a sandstone-hosted roll-front type uranium deposit.

πŸ™Œ Performance (5Yr p.a)

50.42%

πŸ“Š Share price

$0.25 AUD

⚑️ ENERGY

Find Out More

EchoIQ Ltd. engages in the development and application of artificial intelligence for the cardiac diagnostics sector, as well as the supply of software used by the health fund and insurance sector. The company is headquartered in Sydney, New South Wales. The company went IPO on 2010-12-17. The company uses AI-driven technology and proprietary software to improve decision-making in cardiology. The principal activity of the Company is the development of AI products for cardiovascular care. The firm operates through two segments: Echo IQ and Houston We Have Software. The Echo IQ segment is engaged in developing products and services in medical technology. The Houston We Have Software segment offers products and services across other sectors. Its EchoSolv product allows users to assess echocardiographic studies against diagnostic guidelines for structural heart conditions. EchoSolv automatically identifies patients at risk of structural heart disease. EchoSolv improves the standard clinical workflow associated with diagnosis and treatment. The first two conditions addressed by the product are Aortic Stenosis and Mitral Regurgitation.

πŸ™Œ Performance (5Yr p.a)

190.34%

πŸ“Š Share price

$0.30 AUD

πŸ€– TECHNOLOGY